All three lead dual BCL‐2/HDAC compounds (BD‐4‐213, AMC‐4‐154 and SF‐8‐038) triggered AML cell apoptosis, the established mechanisms of activity of both venetoclax and HDACi's. Here, BCL2 is linked to acute myeloid leukemia.